Sigrid Carlsson, MD, PhD, MPH, presented “Year in Review: Emerging Data and Advances in Prostate Cancer Screening” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Carlsson, Sigrid. “Year in Review: Emerging Data and Advances in Prostate Cancer Screening.” October 8, 2024. Accessed Apr 2026. https://grandroundsinurology.com/year-in-review-emerging-data-and-advances-in-prostate-cancer-screening/
Year in Review: Emerging Data and Advances in Prostate Cancer Screening – Summary
Sigrid Carlsson, MD, PhD, MPH, reviews groundbreaking advancements in prostate cancer screening and data from the past year. In this 9-minute presentation, Carlsson highlights the Swedish Berg trial, which showed a 30% reduction in prostate cancer mortality with regular PSA screening, while data from the UK CAP trial confirm that even a single PSA test reduces mortality. She stresses the utility of PSA as the strongest prognostic marker for lethal prostate cancer, with guidelines evolving to recommend tailored screening for high-risk groups like Black men.
Carlsson also shares that advances in MRI have proven pivotal. She references recent trials that underscore the efficacy of MRI-targeted biopsy in minimizing overdiagnosis. Innovations in AI for MRI interpretation promise to improve equity and diagnostic accuracy.
Dr. Carlssson shares that active surveillance is the standard for managing low-risk cancers and addressing concerns about overdiagnosis. Together, these developments mark a transformative year in personalized and effective prostate cancer screening.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Sigrid V. Carlsson, MD, PhD, MPH, is the Division Head of the Clinical Epidemiology of Early Cancer Detection at DKFZ German Cancer Research Center in Heidelberg, Germany. Her research focuses on developing risk-stratified approaches to screening, diagnosis, treatment, and follow-up.
